Abstract 19P
Background
Triple-negaive breast cancer (TNBC) is a highly aggressive subtype with neoadjuvant options historically limited to chemotherapy until the recent success of the KEYNOTE-522 trial. Although TNBC is well known for being associated with constitutional pathogenic BRCA mutations when compared to other types of breast cancer, the genetic profiles of the patients in the KEYNOTE-522 trial are unknown and no subgroup analysis has assessed a possible relationship with treatment efficacy.
Methods
We analysed consecutive index-case genetic consults of TNBC patients (N = 170) between January 2020 and July 2024 in our oncogenetics department. Only patients with treatment history in our center were included. Tumor characteristics, pCR status and the type of chemotherapy agents used were collected. We compared the pCR and non pCR rates according to the genetic status and survival probability distribution stratified by the presence or not of Pembrolizumab and Carboplatin using Fisher’s exact test and the Kaplan-Meier method. A significance threshold of 5% was applied to all statistical analyses.
Results
A total of 132 patients were identified for the analysis. Significant benefits were observed in patients with pCR in terms of EFS (p = 0.001, HR = 0.07 CI 95% 0.02 – 0.21) and OS (p = 0.012, HR = 0.12 CI 95% 0.03 – 0.50), respectively. When comparing patients treated by a neoadjuvant chemotherapy regimen to those treated by pembrolizumab plus chemotherapy, a significantly higher pCR rate was observed with the latter group (p = 0.01). Regarding the presence of pathogenic variants (PV), the following were identified: BRCA1 (N = 10), BRCA2 (N = 3), PALB 2 (N = 1), PMS2 (N = 1), RAD51C (N = 3) and RAD51D (N = 1). 30 patients carried various variants of unknown significance. Notably, all patients carrying a BRCA PV treated with pembrolizumab achieved pCR but results were not statistically significant (p = 0.14).
Conclusions
To our knowledge this is the first descriptive analysis of the genetic landscape of patients with an indication for neoadjuvant Pembrolizumab. Interestingly, all patients carrying pathogenic variants of BRCA treated with pembrolizumab had pCR although results were not statistically significant compared to patients not presenting BRCA PV.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
Resources:
Abstract